CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Summary

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies. A total of 30 patients are planned to be enrolled over a period of 2 years.

Timeline

Start

2016-12-26

Primary completion

2018-12

Completion

2021-12

Drugs

Indications